Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Continue » Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million 23andMe ...

Well, we could find out. Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million ...

Regeneron Pharmaceuticals acquiring genetic testing firm 23andMe for $256 million. The deal follows 23andMe’s Chapter 11 bankruptcy protection filing in March. Transaction excludes telehealth ...

Regeneron Pharmaceuticals is purchasing genetics and biotechnology company 23andMe and has vowed to protect customer data while continuing genome testing services. Regeneron announced the purchase ...

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), Total Health and Research Services business lines, alongside its Biobank and ...

Regeneron Pharmaceuticals has agreed to acquire 23andMe’s consumer genetics business and assets for $256 million, following 23andMe’s Chapter 11 bankruptcy. GOP Calls for Investigation into ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...

TARRYTOWN, N.Y. (AP) — Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...